Protagenic Therapeutics, Inc. (PTIX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.73

From 52W high−79.08%

Volume19071.00

Market cap$1.69M

P/E (TTM)0.3x

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.73

From 52W high

−79.08%

Volume

19071.00

Market cap

$1.69M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

0.3x

RSI (14)

47.5

MomentumView details →

1D Return

+25.43%

YTD Return

−43.85%

SummaryUpdated Jun 1, 2026

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) is a clinical-stage biopharmaceutical company founded to develop novel therapeutics for stress-related neuropsychiatric and mood disorders. The company went public in April 2021 and is headquartered in New York, New York. Protagenic is currently focused on advancing its lead compound PT00114 through clinical trials, representing a potentially breakthrough approach to treating conditions like depression, anxiety, PTSD, and drug addiction through a novel neurobiological mechanism.

Ask drillr about Protagenic Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

0.3x

EV/EBITDA

−0.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

316.93%

ROA (TTM)

261.82%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

+100.00%

EPS YoY

+165.56%

FCF YoY

+20.17%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

+52.83%

MomentumView details →

1D Return

+25.43%

YTD Return

−43.85%

1Y Return

−81.98%

RSI (14)

47.5

vs 50D SMA

+35.82%

vs 200D SMA

+14.49%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

0.66x

Quick Ratio

0.66x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

88.17%

Beats (12Q)

1/12

Next Q EPS Est

−$4.48

Avg Surprise (4Q)

88.17%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

5.46M

Op. CF (TTM)

−2.58M

Next earningsNov 17, 2026 →

Latest newsMore news →

Protagenic Therapeutics received written responses from the U.S. Food and Drug Administration to its Type B pre-IND meeting request for PT00114, with the FDA raising no objection to the planned Phase 1 program design, dose-escalation approach, and CMC and nonclinical packages.31d ago

Similar companies

Voyager Acquisition CorpVRXAW Decoy Therapeutics Inc.DCOY Avenue Therapeutics, Inc.ATXI Virax Biolabs Group LimitedVRAX Propanc Biopharma, Inc.PPCB Iterum Therapeutics plcITRM Find similar companies →

Latest newsMore news →